The Canada Lymph Node Score Project: A Crossover Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Lung CancerNon Small Cell Lung CancerNon-small Cell Lung Cancer Stage INon-small Cell Lung Cancer Stage II
Interventions
DIAGNOSTIC_TEST

Selective Targeted Sampling

Mediastinal lymph nodes are assessed with the CLNS, and only those appearing malignant with the score are biopsied. Triple Normal lymph nodes (normal appearing on PET, CT and EBUS) are not biopsied.

DIAGNOSTIC_TEST

Systematic Sampling

All examined mediastinal lymph nodes are biopsied, regardless of whether they appear normal during PET, CT and EBUS.

Trial Locations (7)

T5H 3V9

Royal Alexandra Hospital, Edmonton

R3A 1R9

Health Sciences Centre, Winnipeg

L8N 4A6

St. Joseph's Healthcare Hamilton, Hamilton

L8S 4L8

McMaster University, Hamilton

M5G 2C4

Toronto General Hospital, Toronto

H2L 4M1

CHUM Endoscopic Tracheo-bronchial and Oesophageal Center, Montreal

H4A 3S9

MUHC Interventional Pulmonology Department, Montreal

All Listed Sponsors
collaborator

Health Sciences Centre, Winnipeg, Manitoba

OTHER

collaborator

Royal Alexandra Hospital

OTHER

collaborator

Toronto General Hospital

OTHER

collaborator

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

collaborator

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

lead

St. Joseph's Healthcare Hamilton

OTHER

NCT04342377 - The Canada Lymph Node Score Project: A Crossover Trial | Biotech Hunter | Biotech Hunter